Peter T. Meinke, PhD
Sanders Director
In 2018, TDI is thrilled to welcome Dr. Peter T. Meinke as the new Sanders Director. Dr. Meinke is an industry veteran with extensive experience across all stages of drug discovery, from target validation through early clinical development. During his long tenure at Merck, his leadership produced one drug – the NS5A inhibitor, elbasvir, for the treatment of chronic hepatitis C – along with 13 development compounds that have advanced into the clinic in seven distinct therapeutic areas. In 2017, Dr. Meinke received the prestigious ACS Heroes of Chemistry Award in recognition of his contributions to the invention of elbasvir. He is co-author of over 90 peer-reviewed publications and co-inventor on more than 35 patents. Dr. Meinke also has significant international leadership experience: from 2008 to 2016, he worked and lived overseas in Shanghai, China, where he directed and mentored global drug discovery research teams while managing attendant business issues.
Current Members
Barry Coller, MD
David Rockefeller Professor
The Rockefeller University
Nathaniel Heintz, PhD
James and Marilyn Simons Professor,
Laboratory of Molecular Biology
The Rockefeller University
Barbara L. Hempstead, MD
Dean of the Weill Cornell Graduate School of Medical Sciences
Weill Cornell Medicine
Francis Lee, MD, PhD
Interim Dean, Weill Cornell Medicine
Interim Provost for Medical Affairs, Cornell University
Richard P. Lifton, MD, PhD
President
The Rockefeller University
Carl Nathan, MD
Chairman of Microbiology and Immunology
Weill Cornell Medicine
David Scheinberg, MD, PhD
Chairman of Molecular Pharmacology and Chemistry Program
Memorial Sloan Kettering Cancer Center
Derek Tan, PhD
Chair, Chemical Biology Program
Sloan Kettering Institute
Memorial Sloan Kettering Cancer Center
Selwyn Vickers, MD, FACS
President and Chief Executive Officer
Memorial Sloan Kettering Cancer Center
Emeritus
Augustine M.K. Choi, MD
Dean, Weill Cornell Medicine
Interim Provost for Medical Affairs, Cornell University
Weill Chairman, Joan and Sanford I. Weill Department of Medicine
Laurie H. Glimcher, MD
President of Dana-Farber Cancer Institute
Marc Tessier-Lavigne, PhD
President
Stanford University
Craig B. Thompson, MD
President and CEO
Memorial Sloan Kettering Cancer Center
Mark Murcko, PhD
Founder & Board Member, Relay Therapeutics
Senior Lecturer, MIT
Mark Duggan, PhD
President, LifeSci Consulting, LLC
Vice President, Neuroscience, AstraZeneca
Takeda Members
Steven Hitchcock, PhD
Matthew Moyle, PhD
CSO, Anaptys Bio, Inc.
Tomas Muselin, PhD
Division Head Rheumatology
University of Washington
David Robinson, PhD
Deputy Dir Vaccine Development
Gates Foundation
Antara Banerjee, PhD
Department of Immunology
Takeda Pharmaceutical Company
Kallo Ray, PhD
VP, Head of Global Biologics
Takeda Pharmaceutical Company
Alan Copenhaver, PhD
Principal Scientist, Oncology
Takeda Pharmaceutical Company